Keywords: EBAF p300 smad2 cited2
Introduction
Congenital heart disease (CHD) is the clinical manifestation of anomalies in the heart and great vessels; it is the leading cause of non-infectious infant mortality, with an incidence about 6/1000 [1, 2] . As the number of patients with CHD increases, the disease has become a significant part of the overall disease burden for which government health agencies are responsible [3] . Ventricular septal defect (VSD) is the most commonly recognized CHD [4] . VSDs take different forms; around 70-80% take the form of a membranous ventricular septal defect, about 20% take the form of a supracristal ventricular septal defect, around 5% take the form of an atrioventricular canal defect, and fewer than 5% of VSDs are muscular defects. VSD genesis is a multifactorial and complex condition in which both genetic and environmental factors play important roles. Although the embryology and physiology of VSDs are widely known, their etiology and pathogenesis are still not very clear.
Recent genetic studies have uncovered a large number of genes in connection with familial and sporadic forms of CHD [5, 6] . Many transcription factors have been described as regulators of cardiacspecific gene expression [7, 8] . For instance, CITED2 (a cAMP-responsive element-binding protein [CBP]/p300-interacting transactivator with ED-rich C-terminal domain) has been found to be essential for normal development of the heart [9] , as evidenced by the fact that mice lacking Cited2 die in utero showing various cardiac malformations including atrial and ventricular septal defects, and overriding aortas [10] . Smad2, another transcriptional factor, has been found to have a detrimental effect on embryo development [11, 12] , but its role in cardiac development has not been clearly clarified.
EBAF, as a Nodal pathway inhibitor [13] has been found to lack any expression [9, 14] in Cited2-null embryos with cardiac malformations. But the correlation between expression patterns of EBAF and cardiac malformations genesis is still unclear. In this paper, for the first time, we show that the expression of EBAF is frequently down-regulated in patients with supracristal ventricular septal defects, membranous ventricular septal defects, and atrioventricular canal type ventricular septal defects. We also show that the down-regulation of the EBAF gene may be partially attributed to the transcriptional modulators smad2 and cited2. Moreover, we find that histone acetyltransferase p300 is involved in the activation of EBAF by inducing the hyperacetylation of histone H4 in the EBAF promoter, indicating that histone acetylation may play an important role in heart development.
Materials and methods

Tissue samples
Fetal myocardial tissue samples were obtained from Shengjing Hospital of China Medical University. Myocardial tissue samples from 16 VSD and 16 normal fetuses at 22-28 weeks of gestation were obtained during surgery for pregnancy termination owing to trauma of the pregnant women. The specimens were immediately frozen in liquid nitrogen and then stored at −80°C until analysis. The study project about roles of gene transcriptional regulation in congenital heart genesis was reviewed and the protocol was approved by the Ethics Committee of the National Research Institute for Family Planning (Permit Number: 2012-7). Informed consent was obtained from each pregnant woman and her family. The study protocol followed the principles of the Declaration of Helsinki.
Cell culture, transfection, and luciferase reporter assay
Human cardiac myocytes (HCM) were maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 100 mg/ml penicillin, and 100 mg/ml streptomycin in a humidified atmosphere containing 5% CO2 at 37°C. Transient transfection HCM cells were performed using the Lipofectamine 2000 (Invitrogen) procedures. Transfected cells were assayed for luciferase reporter activity using a Promega dual-luciferase reporter assay system, and the Renilla luciferase control plasmid pREP7-RLuc was co-transfected for normalization.
Apoptosis assay
Myocardial cells were exposed to deferoxamine mesylate (DFO, 8 mM; Sigma) for 72 h, which served as an established hypoxia model system and induced cell apoptosis. Cells were harvested using trypsin and incubated at room temperature for 5 min in the dark with Annexin V-FITC and propidium iodide according to the instructions of the kit (Roche, Germany). The fluorescence of FITC and PI was analyzed by flow cytometry.
RNA isolation, reverse transcription and real-time PCR
RNA was extracted from the heart tissues using the TRIzol Reagent (Invitrogen) according to the manufacturer's protocol. cDNA was synthesized from 2 μg of RNA using a RNA PCR kit (TaKaRa, Dalian, China). Real-time PCR was performed on an ABI Prism7000 Sequence Detection System (Applied Biosystems), following the manufacturer's protocol, with SYBR Green (TaKaRa, Osaka, Japan) used as a double-stranded DNA-specific fluorescent dye. Primer sequences are reported in the Supplementary material online.
Western blotting
Frozen heart tissues from patients and controls were lysed in buffer. Total protein was applied to a 12% SDS-polyacrylamide gel. After electrophoresis, polyvinylidene fluoride (PVDF) membrane was incubated with anti-EBAF (Santa Cruz), anti-cited2 (Abcam), anti-β-actin (Sigma). The signals were visualized by using the Chemiluminescent Substrate method with the SuperSignal West Pico kit provided by Pierce Co.
CoIP (co-immunoprecipitation) assay
Co-IP was performed in HCM cells as described previously [15] . Total cell extracts from smad2-GFP transfected cells were pre-cleared with 40 μl protein A-agarose at 4°C for 1 h. The supernatant was incubated with the smad2 antibody (Cell Signaling Technology) with gentle shaking for 4°C followed by addition of 40 μl of protein A-agarose for another 3 h. The beads were resuspended in 100 μl of 2× loading buffer and boiled for 10 min. The proteins were separated on a 12% SDS-PAGE gel and then transferred to polyvinylidene fluoride membrane for Western blotting detection with anti-cited2 (Abcam) or anti-p300 antibody (Santa Cruz).
Chromatin immunoprecipitation (ChIP)
ChIP assays were carried out using a kit supplied by Upstate following the manufacturer's protocol. Cells were cross-linked with 2% formaldehyde for 10 min at 37°C, and then lysed in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) with protease inhibitors. After ultrasonication, DNA was immunoprecipitated with antibodies against Ac-H3 (Upstate), Ac-H4 (Upstate), p300 (Santa Cruz), cited2 (Abcam) and smad2 (Cell Signaling Technology). The precipitated chromatin was analyzed by PCR and real time quantitative RCR following the manufacturer's protocol. To calculate the relative abundance of a given gene promoter present in an immunoprecipitate, the following formula was used: Qgene = IPgene/input gene, to calibrate the variation between different samples. Primer sequences are reported in the Supplementary material online. All the experiments were repeated three times, and one of the representative results is shown in the text.
Plasmid constructs
A 600-bp fragment of EBAF enhancer including ASE (asymmetric enhancer) and a 1300-bp fragment of the PITX2C promoter was amplified Fig. 1 . Three-dimensional ultrasound images of fetal hearts. (A) A representative picture of 16 cases of VSDs, which were diagnosed using three-dimensional echocardiography (repeated three times). The representative picture showed the size of the defect in the heart shown here was 4.9 mm. (B) Fetuses that were revealed by the three-dimensional echocardiography to have no VSDs were used as controls.
by polymerase chain reaction (PCR) from the human genomic DNA was cloned into the KpnI and XhoI digested luciferase reporter construct PLG3-basic vector, respectively. The open reading frames of smad2, EBAF, nodal or cited2 were amplified by PCR from human cDNA and inserted into the HindIII and XhoI digested GFP vector or pcDNA3-Flag vector to create smad2-GFP, EBAF-GFP, nodal-GFP or Flag-Cited2 fusion protein, respectively. The pcDNA3.1-p300 plasmid was provided by Huang Baiqu (Institute of Genetics and Cytology, Northeast Normal University, China).
Statistical analysis
Student's t test was used to calculate the statistical significance of the experimental data. The significance level was set as *p b 0.05; #p b 0.05; **p b 0.01; ##p b 0.01. Error bars denote the standard deviations.
Results
Clinical evaluation of ventricular septal defects
Patients underwent a three-dimensional echocardiography to diagnose whether their fetuses showed any indication of VSDs. As shown in Fig. 1A , fetal ventricular septal defect size was 4.9 mm. The threedimensional echocardiography identified 16 VSD fetuses at 22-28 weeks of gestation. The sizes of the defects of 16 VSDs ranged from 4.6-8 mm at 22-28 weeks of gestation. No VSDs were found in the control group, who had been identified during the three-dimensional echocardiography diagnosis phase ( Fig. 1B) . Myocardial tissue samples were obtained during surgery for pregnancy termination owing to trauma of the pregnant women. The 16 cases of fetal VSD were confirmed by autopsy after induced labor. As shown in Table 1 , 13 cases were found to be defects of the membranous septum, 2 were found to be supracristal ventricular septal defects, and 1 was found to be an atrioventricular canal type ventricular septal defect.
Down-regulation of EBAF in the heart tissues of patients with VSDs
We first assessed the expression of EBAF in myocardial tissue samples from 32 patients (16 patients with different subtypes of VSDs and 16 normal fetuses without VSD) using quantitative RT-PCR. The average expression of EBAF in the patients with VSDs was lower than the average value of EBAF expression in 16 normal fetuses without VSD ( Fig. 2A) . Specifically,as shown in Fig. 2B , EBAF was frequently downregulated in membranous ventricular septal defects (one subtype of VSD). Though the expression of EBAF was also down-regulated in supracristal ventricular septal defects and atrioventricular ventricular septal defect (another two subtypes of VSD) in our study (Fig. 2B) , the results should be further confirmed by increasing the numbers of the samples. As confirmed by Western blotting, the level of EBAF protein was significantly down-regulated in the 10 VSD patients with different subtypes of VSDs compared with the 10 normal samples which were selected from the 32 samples mentioned above (Fig. 2C) . The results indicated that the expression of EBAF was, on average, downregulated in the disease tissues of VSD patients, and this may play a significant role in the development of human VSD. 
Down-regulation of EBAF expression in apoptotic cardiomyocytes
We therefore aimed to identify the biological characteristics of the EBAF gene in myocardial cells. The flow cytometry analysis showed DFO-induced apoptosis in cardiomyocytes (Fig. 3A) . Then we assessed the expression of EBAF by comparing control cells and DFO-treated cells using quantitative RT-PCR. As shown in Fig. 3B , the average expression of EBAF in DFO-induced apoptotic cells was lower than the EBAF expression in untreated cells. The results indicated that downregulation of EBAF was associated with cardiomyocyte apoptosis. Thus, down-regulation of EBAF may be potentially involved in heart malformations.
Cited2 played an important role in the expression regulation of EBAF gene
To explore the molecular mechanism of EBAF under-expression in VSD, we first identified the EBAF regulator. Western blotting showed that low expression of cited2 was associated with low expression of EBAF in VSD tissues (Fig. 4A ). Furthermore, we also find that low expression of CITED2 is associated with down-regulation of EBAF in cardiomyocyte apoptosis (Fig. 4B ). In addition, luciferase reporter assays showed that cited2 over-expression up-regulated EBAF promoter activity (Fig. 4C) . Data above showed that cited2 participated in regulating the expression of EBAF gene.
Smad2 cooperates with cited2 to activate the EBAF promoters
The promoter fragments of the EBAF gene contain several GCAT or GTCT motifs, which are potential BR-Smad binding sites [16] . Moreover, through sequence analysis and reference basis, we detected several putative binding sites for the transcription factor smad2 in the ASE region of the EBAF promoter ( Fig. 5A) [20, 21] . Therefore, these data prompted us to examine the possibility of the cooperation of smad2 with cited2 on upregulation of EBAF gene. Firstly, luciferase reporter assays showed that smad2 and cited2 overexpression increased EBAF promoter activity In addition, the location of the EBAF promoter region for ChIP assay has been underlined for specification in the sub- figure. (B) Transcriptional regulators smad2 elevated the promoter activity of EBAF. HCM cells were transfected with EBAF reporter plasmid, together with smad2 expression plasmids; they were also lysed for luciferase reporter assay. (C) cited2 and smad2 cooperatively up-regulated EBAF promoter activity. HCM cells were transfected with EBAF reporter plasmid, together with smad2 and cited2 expression plasmids, and lysed for luciferase reporter assay. (D) smad2 or cited2 over-expression potentiated their binding activities at the EBAF promoter. Samples were immunoprecipitated (IP) with smad2 or cited2 antibodies and amplified by PCR. by 2.1-fold and 1.9-fold, respectively ( Figs. 5B and 4C ). Then we found the promoter activity of the EBAF gene was up-regulated significantly higher upon the co-expression of cited2 and smad2 than transfection with smad2 and cited2, respectively (Fig. 5C ). Furthermore, chromatin immunoprecipitation (ChIP) assays showed that smad2 was able to bind to the EBAF promoter, and that the over-expression of smad2 increased its enrichment at the EBAF promoter ( Fig. 5D, left) . Likewise, cited2 was also present at the EBAF promoter ( Fig. 5D, right) . This indicates that both smad2 and cited2 participate in regulating the expression of EBAF.
The role of p300 in inducing histone H4 hyperacetylation at the EBAF promoter
P300 has a domain with intrinsic histone acetyltransferase (HAT) activity, and it plays an important role in chromatin remodeling [17] . p300 was reported to interact physically with cited2. We examined whether p300 regulated the expression of EBAF. Luciferase reporter assays showed that the promoter activity of EBAF was up-regulated by transfection with p300 expression plasmid (Fig. 6A) . ChIP assays showed that over-expression of p300 increased the enrichment of p300 at the EBAF promoter ( Fig. 6B and Supplemental Fig. S1A ). Furthermore, H4 acetylation levels at the EBAF promoter were also found to increase when there was p300 over-expression. Meanwhile, there was no significant increase in the H3 acetylation levels (Fig. 6C, Supplemental  Fig. S1B and C) . These results clearly indicate that the presence of p300 at the EBAF promoter enhances the acetylation levels of histone H4 at the EBAF promoter.
p300, smad2, and cited2 in the same transcriptional complex
We next examined whether smad2, cited2, and p300 cooperated to regulate the expression of EBAF. Luciferase reporter assays showed that the promoter activity of EBAF gene was significantly increased by 7-fold, which is higher than the increased folds of EBAF promoter activity by transfection with p300, Smad2 and Cited2, respectively (Fig. 7A) . We sought to investigate, using Co-IP assays, whether there was a physical interaction between these transcriptional regulators. In this experiment, HCM cells were transfected with smad2-GFP expression vectors. The immunoprecipitation was conducted with the anti-smad2 antibody and the precipitated proteins were assayed using Western blotting with the antibody against cited2 and p300, respectively. As can be seen in Fig. 7B, smad2 , cited2, and p300 were found to be present in the same complex and worked together to contribute to the regulation of the EBAF expression.
Down-regulation of EBAF caused abnormal activation of NODAL-PITX2C pathway
Finally, we explore the down-stream events of EBAF downregulation that may influence the VDS genesis. Quantitative RT-PCR results showed that PITX2C was up-regulated in the disease tissues of VSD patients (Fig. 8A, B and Supplemental Fig. S3B ). Meanwhile, we found that overexpression of NODAL gene upregulated PITX2C gene promoter activity by luciferase reporter assay. However, the upregulation of PITX2C promoter activity was attenuated when EBAF expression plasmid was co-transfected with NODAL expression plasmid (Fig. 8C) . These results indicated down-regulation of EBAF may partly participated in occurrence of VSD by abnormally activating the NODAL-PITX2C pathway.
Discussion
Observational epidemiological studies of CHD have demonstrated the existence of gene predispositions. However, the genetic basis of the majority of CHD remains unknown, for most CHDs, the basic pathogenetic mechanism of VSD is still unclear. However, to date, very few Fig. 6 . p300 over-expression up-regulates the expression of EBAF by enhancing the acetylation levels of histone H4 at the EBAF promoter. (A) p300 up-regulated EBAF promoter activity by luciferase reporter assay. (B) Over-expression of p300 increased the enrichment of p300 at the EBAF promoter. HCM cells transfected with p300 expression plasmid were subjected to ChIP assays. (C) The acetylation levels of histones H4 were assessed using ChIP assays. HCM cells were transfected with p300 expression plasmid and harvested for ChIP assays. Samples were immunoprecipitated using anti-Ac-H3 or Ac-H4 antibodies, and the precipitated DNAs were amplified using PCR. Fig. 7 . smad2, cited2, and p300 coordinate to up-regulate the expression of EBAF. (A) cited2, p300, and smad2 cooperatively up-regulated EBAF promoter activity. HCM cells were transfected with EBAF reporter plasmid, together with smad2, p300, and cited2 expression plasmids, and lysed for luciferase reporter assays. (B) smad2, cited2, and p300 were presented in the same complex by Co-IP assays. HCM cells transfected with the smad2-GFP expression plasmid were prepared and precipitated with the anti-smad2 antibody, then detected using Western blotting with anti-p300 or anti-cited2 antibody.
VSD-causing genes have been identified. Thus, the identification and characterization of novel genes and proteins associated with VSD remains an important issue. Here, we find that the expression of EBAF was frequently down-regulated in VSD tissues for the first time ( Fig. 2 and Supplemental Fig. S3A ). Furthermore, we also found that downregulation of EBAF was associated with cardiomyocyte apoptosis by Annexin V-FITC and RT-PCR assays (Fig. 3A and B) .
Then, we explored the down-stream events of EBAF down-regulation that may influence the VDS genesis. EBAF, a feedback inhibitor of NODAL signaling, blocks NODAL signaling and rapidly terminates the expression of both NODAL and its target gene such as PITX2C [18] . PITX2C up-regulation was recently reported to be associated with the occurrence of ventricular septal defect [19] . Thus, we speculate that EBAF downregulation may partly lead to VSD by abnormal activation of NODAL pathway. Luciferase reporter assay and quantitative RT-PCR results indicated down-regulation of EBAF may partly participate in occurrence of VSD by abnormally activating NODAL-PITX2C pathway ( Fig. 8 and Supplemental Fig. S3B ). This study established the association of EBAF with VSD genesis.
Here, we report that the expression of EBAF was frequently down-regulated in VSD tissues for the first time ( Fig. 2A) , furthermore, we found that EBAF was frequently down-regulated in membranous ventricular septal defects specifically (Fig. 2B) . Though the expression of EBAF was also down-regulated in supracristal ventricular septal defects and atrioventricular ventricular septal defect (two other subtypes of VSD) in our study (Fig. 2B) , the results should be further confirmed by increasing the numbers of the samples. However, we were not able to confirm this now because of low incidence of the two subtypes of VSD and so no tissues could be acquired right now. The findings of this study indicate that decreased EBAF expression may play an important role in the onset of different subtypes of ventricular septal defects ( Table 1 , Fig. 2 and Supplemental Fig. S3A ).
Low expression of EBAF and its regulatory mechanism of underexpression in patients with VSD have been clarified in this study. Western blotting has indicated that cited2 expression is associated with under-expression of EBAF (Fig. 4) . Further investigation using luciferase reporter assays and ChIP assays suggested that smad2 and cited2 did contribute to the regulation of EBAF expression ( Fig. 5 ). Moreover, one significant finding that has emerged from this study is the role that histone acetylase p300 in mediating cardiac development, through acetylating the histone H4 at the promoter regions of EBAF by luciferase reporter and ChIP assays (Fig. 6A, B and C) . cited2 protein, the transactivator, has no DNA-binding domain. p300, an acetyl transferase, has no DNAbinding domain neither. They should be recruited by transcriptional factor to the promoter of target gene to coactivate gene transcription. Co-IP assays showed that the interaction of smad2 with p300 and cited2 ( Fig. 7) , may facilitate the recruitment of p300 and cited2 to the promoter of EBAF gene. These data suggest that the cooperation of p300, cited2, and smad2 plays a critical role in transcriptional regulation of EBAF in ventricular septal confirmation in the process of cardiac development.
CITED2 plays an important role in the normal development of the heart based on previous findings from gene-targeted mice. However, the correlation between CITED2 gene and congenital cardiac malformation genesis needs to be further validated with human sample. A recent study showed that CITED2 mutations were associated with congenital heart defects genesis by using human blood samples [22] . Our study also found in abnormal expression of CITED2 was correlative with VSD genesis by using patients' tissues ( Fig. 2) . Further study showed that CITED2 participated in EBAF gene transcriptional regulation (Fig. 3) . Thus, our findings provide another important evidence that CITED2 is essential for congenital heart defects genesis. Moreover, we also found the responsive gene of CITED2 in cardiac development.
To conclude, this study established the association of EBAF with VSD genesis with patients' tissues. Further study showed that the expression pattern of EBAF was potentially associated with cardiomyocyte apoptosis by Annexin-V and RT-PCR assays. As shown in Fig. 8D , We also showed that down-regulation of EBAF may partly participate in the occurrence of VSD by abnormally activating the NODAL-PITX2C pathway. Furthermore, our data revealed that histone acetyltransferase p300 was involved in the activation of EBAF through inducing hyperacetylation of histone H4 at the EBAF promoter. Luciferase reporter assays and coimmunoprecipitation revealed that EBAF is regulated by a transcriptional complex including p300, smad2, and cited2. The sketched diagram showed the regulatory mechanisms driven by smad2, cited2, p300, EBAF and NODAL-PITX2C pathway in heart development. Generally speaking, our findings reveal not only a novel regulatory mechanism of EBAF; they also indicate that smad2, cited2, p300 and EBAF play important roles in modulating the confirmation of the ventricular septal.
